Ran Wei

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

Stephen Johnston, Masakazu Toi, Joyce O’Shaughnessy et al. · The Lancet Oncology · 2022 · 566 citations · Full text

Medicine, Endocrinology, Oncology +14

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Nadia Harbeck, Priya Rastogi, Miguel Martín et al. · Annals of Oncology · 2021 · 378 citations · Full text

Medicine, Oncology, Pharmacology +16

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

Priya Rastogi, Joyce O’Shaughnessy, Miguel Martín et al. · Journal of Clinical Oncology · 2024 · 204 citations · Full text

Medicine, Oncology, Pharmacology +15

Prenatal Immune Challenge Is an Environmental Risk Factor for Brain and Behavior Change Relevant to Schizophrenia: Evidence from MRI in a Mouse Model

Qi Li, Charlton Cheung, Ran Wei et al. · PLoS ONE · 2009 · 154 citations · Full text

Life Sciences, Immunology, Neuroscience +15

Two peptides, TsAP-1 and TsAP-2, from the venom of the Brazilian yellow scorpion, Tityus serrulatus: Evaluation of their antimicrobial and anticancer activities

Xiaoxiao Guo, Chengbang Ma, Qiang Du et al. · Biochimie · 2013 · 135 citations

Life Sciences, Pharmacology, Cancer Pharmacology +11